June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Analysis of Th cell-related cytokine production in Behçet’s disease patients with uveitis before and after treatment with infliximab
Author Affiliations & Notes
  • Masaru Takeuchi
    Ophthalmology, National Defense Medical College, Tokorozawa, Japan
  • Atsushi Tanaka
    Ophthalmology, National Defense Medical College, Tokorozawa, Japan
  • Kouzo Harimoto
    Ophthalmology, National Defense Medical College, Tokorozawa, Japan
  • Izumi Mine
    Ophthalmology, National Defense Medical College, Tokorozawa, Japan
  • Tomohito Sato
    Ophthalmology, National Defense Medical College, Tokorozawa, Japan
  • Yoko Karasawa
    Ophthalmology, National Defense Medical College, Tokorozawa, Japan
  • Takayuki Kanda
    Ophthalmology, National Defense Medical College, Tokorozawa, Japan
  • Footnotes
    Commercial Relationships Masaru Takeuchi, None; Atsushi Tanaka, None; Kouzo Harimoto, None; Izumi Mine, None; Tomohito Sato, None; Yoko Karasawa, None; Takayuki Kanda, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1718. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Masaru Takeuchi, Atsushi Tanaka, Kouzo Harimoto, Izumi Mine, Tomohito Sato, Yoko Karasawa, Takayuki Kanda; Analysis of Th cell-related cytokine production in Behçet’s disease patients with uveitis before and after treatment with infliximab. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1718.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Infliximab (Inflix), is an anti- TNFα monoclonal antibody, resolves effectively ocular inflammation in Behçet's disease (BD) patients by suppressing inflammatory process via TNFα. It is reported that treatment with Inflix inhibits Th-cell differentiation into Th17 cells and promotes regulatory T cell production in BD patients with uveitis.<br /> In this study, we examined quantitative changes of cytokines produced by various Th cells specific for ocular tissue antigens before and after treatment with Inflix in BD patients with uveitis.

Methods: Eight BD patients with uveitis during treatment with infliximab were recruited in this study. Peripheral blood mononuclear cells (PBMCs) were obtained before infusion of infliximab and at 1 week after the infusion. PBMCs were also obtained from 10 healthy subjects as the control. Each sample was cultured for 48 hrs with IRBP, and supernatants were collected at the end of culture. IL-1β, IL-4, IL-6, IL-10, IL-17A, IL-17F, IL-21, IL-22, IL-25, IL-31, IL-33, IFN-γ, sCD40L, and TNFα in the supernatants were measured by Bio-Plex kit®. The study was approved by the institutional review board of National Defense Medical College.

Results: All measured cytokines except for IL-25 and IL-33 were higher in BD patients before Inflix infusion compared with BD patients after Inflix infusion or healthy subjects. The levels of IL-4, IL-10, and sCD40L in BD patients after Inflix infusion were comparable with those of healthy subjects, however IL-1β, IL-6, IL-17A, IL-17F, IL-21, IL-22, IL-31, IFN-γ, and TNFα were still higher in BD patients than in healthy subjects.

Conclusions: It was indicated that cytokines produced by Th cells stimulated with IRBP in BD patients were suppressed by Inflix treatment, which was not only cytokines promoting ocular inflammation but also the inhibitory cytokines, but that the levels of most cytokines did not reach to those of healthy subjects.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×